Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.

Phase 3

Completed

Interventions: Drug: Placebo tablets
Drug: Itraconazole 200mg tablets
Drug: Itraconazole 100mg capsules

Brief Summary: Onychomycosis is a common condition accounting for approximately half of all nail disorders. It is most commonly caused by dermatophytes. Itraconazole has been approved for the treatment of onychomycosis in the United States with an approved dosage regimen for the treatment of onychomycosis of the toenail of once daily (QD) treatment with 200mg of itraconazole (two 100 mg capsules) for 12 weeks. Barrier Therapeutics has developed a 200 mg tablet which could be used in a more convenient one-tablet-per-day dosing regimen. This clinical trial will compare the efficacy and safety of this new tablet formulation with itraconazole capsules and placebo.

Detailed Description: Onychomycosis is common and accounts for about half of all nail disorders. Usually the cause is due to dermatophytes, either Trichophyton rubrum (71%) or Trichophyton mentagrophytes (20%) but may also be due to yeast infection, usually Candida albicans.

The prevalence of onychomycosis in the United States population as a whole is 13% and is more prevalent in the elderly (60%). Onychomycosis of the toenail recurs and is thought to have a genetic component.

Onychomycosis can result in permanent nail deformity. This disease has a significant impact on the patient's quality of life (e.g., concern with the appearance of the toenails and fingernails, interference with wearing shoes, walking and sports activities).

Itraconazole has been approved for the treatment of onychomycosis in the United States since the mid-nineteen-nineties. The approved dosage regimen for treatment of onychomycosis of the toenail is once daily (QD) treatment with 200 mg of itraconazole (Sporanox®, Janssen Pharmaceutical Products, L.P., Titusville, NJ, USA) for 12 weeks. The approved dosage form is a 100mg capsule. Barrier Therapeutics has developed a 200mg tablet which could be used in a more convenient one-tablet-per-day dosing regimen.

This clinical trial will compare the efficacy and safety of this new tablet formulation with itraconazole capsules and placebo.

Recruitment & Eligibility

Inclusion Criteria

Clinical diagnosis of onychomycosis of at least one great toenail
Percent Nail Involvement Score of the more severely affected great toenail (the Target Toenail) must be between 2 and 3 (25-75% of the nail unit).
Length of Unaffected Part of the Target Toenail ≥2mm
Direct microscopic examination with KOH that is positive for the hyphae associated with dermatophytes on the target toenail
Subjects must have signed informed consent
If the subject is woman of childbearing potential, she must have a negative urine pregnancy test and agree to use an effective form of birth control until the first menses after 60 days following the last dose of study medication.

Exclusion Criteria

Onychomycosis caused by Candida spp. without the presence of a dermatophyte
Participation in a clinical trial for the systemic treatment of onychomycosis of the toenail within 24 weeks prior to Visit 1
Use of systemic antifungals within 12 weeks prior to Visit 1
Use of topical antifungal nail lacquer within 30 days prior to Visit 1
Use of any other topical onychomycosis treatment on any toenail within 7 days prior to Visit 1
Evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF
Known liver disease or a history of liver toxicity with other drugs
Use of systemic immunosuppressants

Arm && Interventions

Group	Intervention	Description
Placebo tablets	Placebo tablets	The itraconazole 200-mg tablets and placebo tablets exactly matched one another and were white to slightly grey in color, were oblong and biconvex in shape, and were melt-extrusion, film-coated.
Itraconazole tablets	Itraconazole 200mg tablets	Itraconazole 200 mg tablets
Itraconazole capsules	Itraconazole 100mg capsules	Two Itraconazole 100 mg capsules were taken daily.

Primary Outcome Measures

Name	Time	Method
Clinical and Mycological Cure of Target Toenail	1 year	This study was designed to evaluate the superiority of itraconazole tablets to placebo tablets. Clinical Cure was defined as an IGA score of 0 for the target toenail; Mycological Cure was defined as a negative potassium hydroxide (KOH) exam and a negative culture for dermatophytes of the target toenail.
Complete Cure - Itraconazole Tablets Compared to Itraconazole Capsules	12 months	The primary efficacy endpoint was Compete Cure (consisting of a Clinical Cure and a Mycological Cure) at week 52. In this study, Clinical Cure was defined as an Investigator's Global Assessment (IGA) score of 0 for the target toenail; Mycological Cure was defined as a negative potassium hydroxide (KOH) examination and a negative culture outcome for dermatophytes of the target toenail. The efficacy analyses were conducted to demonstrate the non-inferiority of 1 itraconazole 200-mg tablet to 2 itraconazole 100-mg capsule.

Secondary Outcome Measures

Name	Time	Method
Clinical Improvement of the Target Toenail	12 months	Clinical Improvement consisted of a mycological cure and an Investigator's Global Assessment (IGA) score less than or equal to 1 at week 52. The Investigator's Global Assessment (IGA) assesses the overall severity of onychomycosis on the target toenail and takes into consideration, onycholysis, hyperkeratosis and percent nail involvement. 0 = Clinical Cure: No evidence of onychomycosis. 1 = Clinical Improvement: Minimal evidence of onychomycosis. 2 = Mild: ≤25% dystrophy and/or onycholysis. 3 = Moderate: ≤50% dystrophy with onycholysis. 4 = Severe: \>50% dystrophy with onycholysis.
Clinical Improvement Compared to Placebo	12 months	Clinical Improvement consisted of a mycological cure and an Investigator's Global Assessment (IGA) score less than or equal to 1 at week 52. The Investigator's Global Assessment(IGA)assesses the overall severity of onychomycosis on the target toenail and takes into consideration, onycholysis, hyperkeratosis and percent nail involvement. 0 = Clinical Cure: No evidence of onychomycosis. 1 = Clinical Improvement: Minimal evidence of onychomycosis. 2 = Mild: ≤25% dystrophy and/or onycholysis. 3 = Moderate: ≤50% dystrophy with onycholysis. 4 = Severe: \>50% dystrophy with onycholysis.

Locations (68): Radiant Research -Birmingham
🇺🇸
Birmingham, Alabama, United States
University of Alabama School of Medicine
🇺🇸
Birmingham, Alabama, United States
Radiant Research - Tucson
🇺🇸
Tuscon, Arizona, United States
Burke Pharmaceutical Research
🇺🇸
Hot Springs, Arkansas, United States
East Bay Dermatology Medical Group Inc.
🇺🇸
Fremont, California, United States
Skin Surgey Medical Group
🇺🇸
San Diego, California, United States
Therapeutics Clinical Research
🇺🇸
San Diego, California, United States
University of California
🇺🇸
San Francisco, California, United States
Radiant Research - Santa Rosa
🇺🇸
Santa Rosa, California, United States
Meridian Skincare
🇺🇸
Englewood, Colorado, United States
Scroll for more (58 remaining)
Radiant Research -Birmingham
🇺🇸Birmingham, Alabama, United States